Related Experiment Video
Updated: Jun 14, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
95
Therapeutic Maintenance of Janus Kinase Inhibitors in Real Life for Rheumatoid Arthritis: Retrospective Study
Camille Farnos1, Vincent Barbier2, Marie Doussiere1
1Department of Rheumatology, Amiens University Hospital, 80054 Amiens, France.
Journal of Clinical Medicine
|August 29, 2024
Summary
This study found that the persistence rates of four Janus kinase inhibitors (JAKis) for rheumatoid arthritis were similar in real-world use. These findings suggest comparable long-term efficacy for these targeted oral therapies.
Area of Science:
- Rheumatology
- Pharmacology
- Clinical Medicine
Background:
- Janus kinase inhibitors (JAKis) represent a novel class of targeted oral therapies for rheumatoid arthritis (RA).
- Evaluating the real-world efficacy and safety of available JAKi molecules is crucial for clinical decision-making.
Purpose of the Study:
- To assess the real-life efficacy and safety profiles of four Janus kinase inhibitors (tofacitinib, baricitinib, filgotinib, upadacitinib) in patients with RA.
- To evaluate the maintenance rate at 24 months as an indicator of long-term treatment effectiveness and tolerability.
Main Methods:
- Retrospective, single-center observational study.
- Inclusion of 76 patients with RA treated with JAKis between October 2017 and December 2023.
- Assessment of therapeutic maintenance rates at 24 months.
Main Results:
- The overall 2-year therapeutic maintenance rate for all JAKis was 50%.
- Average maintenance duration was 8.6 months, with no significant differences observed across the four JAKi molecules.
- Baricitinib was the most frequently prescribed JAKi, with a 50% discontinuation rate after two years.
Conclusions:
- Persistence rates among the four JAKi molecules in daily practice did not significantly differ.
- The study supports the long-term efficacy of these targeted oral therapies in managing rheumatoid arthritis.
- Real-world data indicate comparable outcomes for tofacitinib, baricitinib, filgotinib, and upadacitinib in RA treatment.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
122
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
147
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
147